Publications:

---

PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.

Molecular Cancer

Kelm, Jeremy M JM; Pandey, Deepti S DS; Malin, Evan E; Kansou, Hussein H; Arora, Sahil S; Kumar, Raj R; Gavande, Navnath S NS

Publication Date: 2023-03-30

Variant appearance in text: EGFR: C797X

PubMed Link: 36991452

Variant Present in the following documents:

• Main text
• 12943_2022_Article_1707.pdf

View BVdb publication page

---

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.

Frontiers In Oncology

Kian, Waleed W; Krayim, Bilal B; Alsana, Hadel H; Giles, Betsy B; Purim, Ofer O; Alguayn, Wafeek W; Alguayn, Farouq F; Peled, Nir N; Roisman, Laila C LC

Publication Date: 2023

Variant appearance in text: EGFR: C797X

PubMed Link: 36923435

Variant Present in the following documents:

• Main text
• fonc-13-1124949.pdf

View BVdb publication page

---

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine.

Journal Of Clinical Medicine

Sattler, Martin M; Mambetsariev, Isa I; Fricke, Jeremy J; Tan, Tingting T; Liu, Sariah S; Vaidehi, Nagarajan N; Pisick, Evan E; Mirzapoiazova, Tamara T; Rock, Adam G AG; Merla, Amartej A; Sharma, Sunil S; Salgia, Ravi R

Publication Date: 2023-03-01

Variant appearance in text: EGFR: C797X

PubMed Link: 36902723

Variant Present in the following documents:

• jcm-12-01936.pdf

View BVdb publication page

---

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.

Nature Communications

Chmielecki, Juliann J; Mok, Tony T; Wu, Yi-Long YL; Han, Ji-Youn JY; Ahn, Myung-Ju MJ; Ramalingam, Suresh S SS; John, Thomas T; Okamoto, Isamu I; Yang, James Chih-Hsin JC; Shepherd, Frances A FA; Bulusu, Krishna C KC; Laus, Gianluca G; Collins, Barbara B; Barrett, J Carl JC; Hartmaier, Ryan J RJ; Papadimitrakopoulou, Vassiliki V

Publication Date: 2023-02-27

Variant appearance in text: EGFR: C797X

PubMed Link: 36849516

Variant Present in the following documents:

• Main text
• 41467_2023_Article_35962.pdf

View BVdb publication page

---

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer.

Therapeutic Advances In Medical Oncology

Lee, Jiyun J; Piotrowska, Zofia Z; Soo, Ross R; Cho, Byoung Chul BC; Lim, Sun Min SM

Publication Date: 2022

Variant appearance in text: EGFR: C797X

PubMed Link: 36544540

Variant Present in the following documents:

• Main text
• 10.1177_17588359221144099.pdf

View BVdb publication page

---

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.

Journal Of Hematology & Oncology

Fu, Kai K; Xie, Fachao F; Wang, Fang F; Fu, Liwu L

Publication Date: 2022-12-08

Variant appearance in text: EGFR: C797X

PubMed Link: 36482474

Variant Present in the following documents:

• Main text
• 13045_2022_Article_1391.pdf

View BVdb publication page

---

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.

Frontiers In Oncology

Takamori, Shinkichi S; Seto, Takashi T; Yamaguchi, Masafumi M; Kinoshita, Fumihiko F; Fujishita, Takatoshi T; Ito, Kensaku K; Toyozawa, Ryo R; Shoji, Fumihiro F; Okamoto, Tatsuro T

Publication Date: 2022

Variant appearance in text: EGFR: C797X

PubMed Link: 36313664

Variant Present in the following documents:

• Main text
• fonc-12-965741.pdf

View BVdb publication page

---

Osimertinib+Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor Mutated MET-Amplified Non-Small Cell Lung Cancer: TATTON.

Cancer Discovery

Hartmaier, Ryan J RJ; Markovets, Aleksandra A AA; Ahn, Myung Ju MJ; Sequist, Lecia V LV; Han, Ji-Youn JY; Cho, Byoung Chul BC; Yu, Helena A HA; Kim, Sang-We SW; Yang, James Chih-Hsin JC; Lee, Jong-Seok JS; Su, Wu-Chou WC; Kowalski, Dariusz M DM; Orlov, Sergey S; Ren, Song S; Frewer, Paul P; Ou, Xiaoling X; Cross, Darren Ae DA; Kurian, Nisha N; Cantarini, Mireille M; Janne, Pasi A PA

Publication Date: 2022-10-20

Variant appearance in text: EGFR: C797X

PubMed Link: 36264123

Variant Present in the following documents:

• Main text
• 98.pdf

View BVdb publication page

---

Minimal residual disease in EGFR-mutant non-small-cell lung cancer.

Frontiers In Oncology

Bain, Nathan T NT; Wang, Yang Y; Arulananda, Surein S

Publication Date: 2022

Variant appearance in text: EGFR: C797X

PubMed Link: 36212398

Variant Present in the following documents:

• Main text
• fonc-12-1002714.pdf

View BVdb publication page

---

[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC 
(2022 Version)].

Zhongguo Fei Ai Za Zhi = Chinese Journal Of Lung Cancer

, ; ,

Publication Date: 2022-09-20

Variant appearance in text: EGFR: C797X

PubMed Link: 36172727

Variant Present in the following documents:

• Main text
• zgfazz-25-9-627.pdf

View BVdb publication page

---

High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy.

Biomedicines

Sung, Ji-Youn JY; Park, Dong-Won DW; Lee, Seung-Hyeun SH

Publication Date: 2022-08-29

Variant appearance in text: EGFR: C797X

PubMed Link: 36140210

Variant Present in the following documents:

• Main text
• biomedicines-10-02109.pdf

View BVdb publication page

---

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.

Frontiers In Pharmacology

Qian, Xiaoyu X; Guo, Xiaodan X; Li, Ting T; Hu, Wei W; Zhang, Lin L; Wu, Caisheng C; Ye, Feng F

Publication Date: 2022

Variant appearance in text: EGFR: c797x

PubMed Link: 36071838

Variant Present in the following documents:

• Main text
• fphar-13-926890.pdf

View BVdb publication page

---

An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.

Frontiers In Oncology

Qi, Yuexiao Y; Xia, Xiaojun X; Shao, Lihua L; Guo, Liyun L; Dong, Yumei Y; Tian, Jinhui J; Xu, Lijun L; Niu, Ruijun R; Wei, Shihong S

Publication Date: 2022

Variant appearance in text: EGFR: C797X

PubMed Link: 35978809

Variant Present in the following documents:

• Main text
• fonc-12-616546.pdf

View BVdb publication page

---

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.

Cancers

Koulouris, Andreas A; Tsagkaris, Christos C; Corriero, Anna Chiara AC; Metro, Giulio G; Mountzios, Giannis G

Publication Date: 2022-07-08

Variant appearance in text: EGFR: C797X

PubMed Link: 35884398

Variant Present in the following documents:

• Main text
• cancers-14-03337.pdf

View BVdb publication page

---

Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

Current Oncology (Toronto, Ont.)

Olsen, Steven S; Liao, Jiemin J; Hayashi, Hidetoshi H

Publication Date: 2022-07-08

Variant appearance in text: EGFR: C797X

PubMed Link: 35877242

Variant Present in the following documents:

• Main text
• curroncol-29-00382.pdf

View BVdb publication page

---

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.

Journal Of Hematology & Oncology

Shi, Kunyu K; Wang, Guan G; Pei, Junping J; Zhang, Jifa J; Wang, Jiaxing J; Ouyang, Liang L; Wang, Yuxi Y; Li, Weimin W

Publication Date: 2022-07-15

Variant appearance in text: EGFR: C797X

PubMed Link: 35840984

Variant Present in the following documents:

• Main text
• 13045_2022_Article_1311.pdf

View BVdb publication page

---

Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.

Frontiers In Oncology

Shen, Fangfang F; Liang, Naixin N; Fan, Zaiwen Z; Zhao, Min M; Kang, Jing J; Wang, Xifang X; Hu, Qun Q; Mu, Yongping Y; Wang, Kai K; Yuan, Mingming M; Chen, Rongrong R; Guo, Wei W; Dong, Guilan G; Zhao, Jun J; Bai, Jun J

Publication Date: 2022

Variant appearance in text: EGFR: C797X

PubMed Link: 35814426

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

International Journal Of Molecular Sciences

Bertoli, Elisa E; De Carlo, Elisa E; Del Conte, Alessandro A; Stanzione, Brigida B; Revelant, Alberto A; Fassetta, Kelly K; Spina, Michele M; Bearz, Alessandra A

Publication Date: 2022-06-22

Variant appearance in text: EGFR: C797x

PubMed Link: 35805940

Variant Present in the following documents:

• Main text
• ijms-23-06936.pdf

View BVdb publication page

---

Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review.

Translational Lung Cancer Research

Huang, Yingbo Y; Cho, Hyeong Joo HJ; Stranger, Barbara E BE; Huang, R Stephanie RS

Publication Date: 2022-05

Variant appearance in text: EGFR: C797X

PubMed Link: 35693273

Variant Present in the following documents:

• Main text

View BVdb publication page

---

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).

Journal Of Clinical Medicine

Raphael, Ari A; Dudnik, Elizabeth E; Hershkovitz, Dov D; Jain, Suyog S; Olsen, Steve S; Soussan-Gutman, Lior L; Ben-Shitrit, Taly T; Dvir, Addie A; Nechushtan, Hovav H; Peled, Nir N; Onn, Amir A; Agbarya, Abed A; On Behalf Of The Israel Lung Cancer Group,

Publication Date: 2022-04-28

Variant appearance in text: EGFR: C797X

PubMed Link: 35566609

Variant Present in the following documents:

• Main text
• jcm-11-02475.pdf

View BVdb publication page

---

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.

Frontiers In Oncology

Mahfoudhi, Emna E; Ricordel, Charles C; Lecuyer, Gwendoline G; Mouric, Cécile C; Lena, Hervé H; Pedeux, Rémy R

Publication Date: 2022

Variant appearance in text: EGFR: C797X

PubMed Link: 35463360

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.

Cancers

Ríos-Hoyo, Alejandro A; Moliner, Laura L; Arriola, Edurne E

Publication Date: 2022-04-12

Variant appearance in text: EGFR: C797X

PubMed Link: 35454838

Variant Present in the following documents:

• Main text
• cancers-14-01931.pdf

View BVdb publication page

---

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.

Scientific Reports

Koyama, Kenichi K; Miura, Satoru S; Watanabe, Satoshi S; Shoji, Satoshi S; Koshio, Jun J; Hayashi, Yoshiki Y; Ishikawa, Daisuke D; Sato, Ko K; Miyabayashi, Takao T; Okajima, Masaaki M; Ota, Takeshi T; Tanaka, Tomohiro T; Matsumoto, Naoya N; Kuriyama, Hideyuki H; Abe, Tetsuya T; Nozaki, Koichiro K; Ichikawa, Kosuke K; Kondo, Rie R; Tanaka, Hiroshi H; Kikuchi, Toshiaki T

Publication Date: 2022-04-16

Variant appearance in text: EGFR: C797X

PubMed Link: 35430596

Variant Present in the following documents:

• Main text
• 41598_2022_Article_10288.pdf

View BVdb publication page

---

ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression?

Lung Cancer (Auckland, N.Z.)

Nagasaka, Misako M; Ou, Sai-Hong Ignatius SI

Publication Date: 2022

Variant appearance in text: EGFR: C797X

PubMed Link: 35378922

Variant Present in the following documents:

• Main text
• lctt-13-13.pdf

View BVdb publication page

---

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report.

Translational Cancer Research

Nozaki, Koichiro K; Watanabe, Satoshi S; Nishio, Kazuto K; Sakai, Kazuko K; Kikuchi, Toshiaki T

Publication Date: 2022-01

Variant appearance in text: EGFR: C797X

PubMed Link: 35261905

Variant Present in the following documents:

• Main text
• tcr-11-01-295.pdf

View BVdb publication page

---

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Cancer Science

Koga, Takamasa T; Suda, Kenichi K; Mitsudomi, Tetsuya T

Publication Date: 2022-03

Variant appearance in text: EGFR: C797X

PubMed Link: 34997674

Variant Present in the following documents:

• Main text
• CAS-113-815.pdf

View BVdb publication page

---

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.

Cancers

Reita, Damien D; Pabst, Lucile L; Pencreach, Erwan E; Guérin, Eric E; Dano, Laurent L; Rimelen, Valérie V; Voegeli, Anne-Claire AC; Vallat, Laurent L; Mascaux, Céline C; Beau-Faller, Michèle M

Publication Date: 2021-09-30

Variant appearance in text: EGFR: C797X

PubMed Link: 34638411

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.

Esmo Open

Di Noia, V V; D'Aveni, A A; D'Argento, E E; Rossi, S S; Ghirardelli, P P; Bortolotti, L L; Vavassori, V V; Bria, E E; Ceresoli, G L GL

Publication Date: 2021-10-08

Variant appearance in text: EGFR: C797X

PubMed Link: 34634633

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective.

Pharmaceutics

Zhu, Jing J; Yang, Qian Q; Xu, Weiguo W

Publication Date: 2021-09-18

Variant appearance in text: EGFR: C797X

PubMed Link: 34575576

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer.

Pharmaceutics

Aboubakar Nana, Frank F; Ocak, Sebahat S

Publication Date: 2021-09-15

Variant appearance in text: EGFR: C797X

PubMed Link: 34575554

Variant Present in the following documents:

• Main text
• pharmaceutics-13-01478.pdf

View BVdb publication page

---

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications.

Cancers

Pathak, Ranjan R; Villaflor, Victoria M VM

Publication Date: 2021-09-16

Variant appearance in text: EGFR: C797X

PubMed Link: 34572868

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.

Cancer Discovery

Jänne, Pasi A PA; Baik, Christina C; Su, Wu-Chou WC; Johnson, Melissa L ML; Hayashi, Hidetoshi H; Nishio, Makoto M; Kim, Dong-Wan DW; Koczywas, Marianna M; Gold, Kathryn A KA; Steuer, Conor E CE; Murakami, Haruyasu H; Yang, James Chih-Hsin JC; Kim, Sang-We SW; Vigliotti, Michele M; Shi, Rong R; Qi, Zhenhao Z; Qiu, Yang Y; Zhao, Lihui L; Sternberg, David D; Yu, Channing C; Yu, Helena A HA

Publication Date: 2022-01

Variant appearance in text: EGFR: C797X

PubMed Link: 34548309

Variant Present in the following documents:

• Main text
• 74.pdf

View BVdb publication page

---

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?-a narrative review.

Translational Lung Cancer Research

Dempke, Wolfram C M WCM; Fenchel, Klaus K

Publication Date: 2021-06

Variant appearance in text: EGFR: C797X

PubMed Link: 34295669

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.

European Respiratory Review : An Official Journal Of The European Respiratory Society

Abdayem, Pamela P; Planchard, David D

Publication Date: 2021-09-30

Variant appearance in text: EGFR: C797X

PubMed Link: 34289984

Variant Present in the following documents:

• Main text
• ERR-0294-2020.pdf

View BVdb publication page

---